Showing results (231-240 of 9,661) with videos related to
Sort By:
Pageof 967
Leukemia|June 25, 2011
p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemiaK P Ng, Q Ebrahem, S Negrotto, et al.Leukemia|August 10, 2011
Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemiaF Damm, T Bunke, F Thol, et al.Leukemia|August 24, 2011
The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activityM M Reddy, M S Fernandes, A Deshpande, et al.Leukemia|August 24, 2011
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic propertiesK C Goh, V Novotny-Diermayr, S Hart, et al.Leukemia|August 27, 2011
Commentary: does immune suppression increase risk of developing acute myeloid leukemia?R P Gale, G OpelzLeukemia|August 27, 2011
(+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivoG A S dos Santos, R S Abreu e Lima, C R Pestana, et al.Leukemia|September 1, 1990
Chronic myeloid leukemia arising in a progenitor common to T cells and myeloid cellsA C Schuh, D R Sutherland, W Horsfall, et al.Leukemia|June 22, 2011
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignanciesS Hart, K C Goh, V Novotny-Diermayr, et al.Leukemia|June 22, 2011
Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patientsA Pardanani, P Guglielmelli, T L Lasho, et al.Leukemia|July 13, 2011
Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myelomaM A Dimopoulos, M Hussein, A S Swern, et al.Pageof 967